Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
BerGenBio ASA
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06469138CT.gov A Study to Investigate 14C-bemcentinib in Healthy Male Subjects | — | Completed | — | — | — |
NCT03649321CT.gov Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Pancreatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bemcentinib (this asset) | BerGenBio ASA | P1/2 | CCC · 50 |
| Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer | Chinese PLA General Hospital | P4 | BBB |
| Metformin | State University of New York - Downstate Medical Center | P2 | BBB |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Jonsson Comprehensive Cancer Center | P2/3 | BB |
| Olaparib | MOMA Therapeutics | P2 | BB |
| Tunlametinib | Chinese PLA General Hospital | P4 | BB |
+42 more in the Malignant Pancreatic Neoplasm cohort
Other indications for Bemcentinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic Syndrome | — | P2 | CCC · 54 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 52 |
| Acute Myeloid Leukemia | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, DimerChinese PLA General HospitalBBB
- MetforminState University of New York - Downstate Medical CenterBBB
- FluorouracilumJonsson Comprehensive Cancer CenterBBB
- IrinotecanJonsson Comprehensive Cancer CenterBB
- OxaliplatinJonsson Comprehensive Cancer CenterBB
Citation
Floatz Terminal. Bemcentinib in Malignant Pancreatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bemcentinib-malignant-pancreatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →